BerGenBio reports Phase Ib/II data for bemcentinib in melanoma

BerGenBio ASA (OSE:BGBIO) reported data from 19 patients with metastatic melanoma in a Phase Ib/II trial evaluating bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) or Tafinlar dabrafenib/Mekinist trametinib from Novartis AG (NYSE:NVS; SIX:NOVN). The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

In eight patients who received bemcentinib plus Keytruda, the combination led to three partial responses and two cases of stable disease. Keytruda alone led to one partial response and two cases of stable disease in three patients...